IAP Antibody (AP1B9): sc-53335
- IAP Antibody (AP1B9) is a mouse monoclonal IgG1 κ, cited in 1 publications, provided at 200 µg/ml
- raised against calf intestinal phosphatase
- recommended for detection of IAP of bovine origin by IF
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IAP Antibody (AP1B9). This work is in progress.
IAP Antibody (AP1B9) is a mouse monoclonal IgG1 antibody that detects intestinal alkaline phosphatase (IAP) in bovine samples through immunofluorescence (IF) applications. Anti-IAP antibody (AP1B9) plays a crucial role in studying the digestive system′s brush-border enzyme, which is significantly upregulated during the differentiation of small intestinal epithelial cells. IAP is essential for limiting fat absorption and is involved in the trans-cellular transport and formation of chylomicrons, which are vital for lipid metabolism. IAP operates optimally at high pH levels, where IAP removes phosphate groups from proteins and the 5′ ends of DNA and RNA, thereby influencing various biochemical pathways. IAP is particularly notable in tissues such as the liver, bile ducts, placenta, and bone, with IAP levels serving as a potential biomarker for various conditions, including bone and liver diseases. Additionally, serum IAP levels can vary among different ABO blood groups, with individuals of blood group O or B exhibiting higher prevalence, which may also affect fatty acid metabolism. IAP (AP1B9) monoclonal antibody is an invaluable tool for researchers studying the intricate roles of intestinal alkaline phosphatase in bovine models, providing insights into its function and implications in health and disease.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IAP Antibody (AP1B9) References:
- Mammalian mitochondrial IAP binding proteins. | Vaux, DL. and Silke, J. 2003. Biochem Biophys Res Commun. 304: 499-504. PMID: 12729584
- IAP-targeted therapies for cancer. | LaCasse, EC., et al. 2008. Oncogene. 27: 6252-75. PMID: 18931692
- Antagonists of IAP proteins as cancer therapeutics. | Dynek, JN. and Vucic, D. 2013. Cancer Lett. 332: 206-14. PMID: 20685035
- IAP proteins as targets for drug development in oncology. | Dubrez, L., et al. 2013. Onco Targets Ther. 9: 1285-304. PMID: 24092992
- Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities. | Fulda, S. 2014. Leukemia. 28: 1414-22. PMID: 24487414
- IAP gene deletion and conditional knockout models. | Silke, J. and Vaux, DL. 2015. Semin Cell Dev Biol. 39: 97-105. PMID: 25545814
- The IAP Protein Family, SMAC Mimetics and Cancer Treatment. | Philchenkov, A. and Miura, K. 2016. Crit Rev Oncog. 21: 185-202. PMID: 27915971
- IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development. | Ali, R., et al. 2018. Curr Med Chem. 25: 3768-3795. PMID: 29532750
- Regulation of innate and adaptive antitumor immunity by IAP antagonists. | Dougan, SK. and Dougan, M. 2018. Immunotherapy. 10: 787-796. PMID: 29807457
- Intestinal alkaline phosphatase (IAP, IAP Enhancer) attenuates intestinal inflammation and alleviates insulin resistance. | Gao, C., et al. 2022. Front Immunol. 13: 927272. PMID: 35958560
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IAP Antibody (AP1B9) | sc-53335 | 200 µg/ml | $322.00 |